



Systemic Treatment and Innovative Diagnostics of Advanced Prostate Cancer

Guest Editors:

Prof. Dr. Alexander Kretschmer

Department of Urology, LMU
Klinikum, Ludwig-Maximilians
University Munich, 81377 Munich,
Germany

Dr. Takayuki Sumiyoshi

Vancouver Prostate Centre,
Department of Urologic Science,
University of British Columbia,
Vancouver, BC V6T 1Z4, Canada

Deadline for manuscript
submissions:
closed (20 August 2022)

Message from the Guest Editors

The therapeutic landscape of advanced prostate cancer is rapidly evolving and conventional androgen deprivation monotherapy is increasingly being replaced by a plethora of sophisticated combination therapies, including next-generation anti-androgens such as enzalutamide, apalutamide, and darolutamide, as well as abiraterone acetate and docetaxel. However, correct risk stratification and patient selection are still being debated, and evidence regarding clinical, diagnostic, and molecular prognostic and predictive biomarkers is still subpar. In addition, the implementation of PSMA-based imaging as well as LuPSMA and AcPSMA radioligand therapy is ongoing and evidence regarding its clinical use in advanced prostate cancer is steadily growing. Again, patient stratification and the implementation of novel imaging findings in the existing literature are still subject to debate. In this Special Issue, we aim to address relevant and ongoing debates regarding the systemic treatment of this disease as well as the current diagnostic strategies used for advanced prostate cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)